Rejuva: Our potential solution for the remission of obesity and type 2 diabetes
Rejuva is a novel, locally administered, AAV gene therapy platform currently in preclinical development to improve islet function. We believe the platform represents a major advance in incretin-based therapies because it is designed to be a one-time gene therapy platform to enable durable weight loss and long-term remission of type 2 diabetes by altering metabolic hormone response in the pancreatic islet cells of patients with those diseases.
3 key elements of Rejuva gene therapy.
Proprietary delivery system to enable local delivery of advanced therapies directly to pancreas.
Low dose viral vectors with high transduction efficiency and limited systemic biodistribution.
Durable alteration of metabolic hormone response in the islets with tissue-restricted transgenes.
Learn more about Rejuva.
Rejuva® is in early development and not approved by any regulatory body for investigational or commercial use.